Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide on Hepatic Fat in T2DM
NCT01432405Phase 4Completed
- Sponsor
- Baylor College of Medicine
- Start
- Jun 2007
- Primary completion
- Jul 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of exenatide in type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) (2 arms), sponsored by Baylor College of Medicine. Primary endpoint: Hepatic Fat Content at 1 year. Started Jun 2007; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT01432405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01432405.